All In Biotech

Drug Trial Radar · NCT07284654

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

A Phase 3, Randomized, Double-Blind, Active-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Subjects 50 Years of Age and Older With Immunobridging to Subjects 18-49 Years of Age

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 4,049 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,049

Actual

Start

Dec 1, 2025

Primary completion

Sep 17, 2026

Study completion Sep 17, 2026

Sponsor

Lead sponsor
Vaxcyte, Inc.Industry
Sponsor type
Industry
First posted
Dec 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objectives of this study are to evaluate the safety, tolerability, immunologic noninferiority (for shared serotypes) and immunologic superiority (for novel serotypes) of VAX-31 compared to PCV21 and PCV20 in adults ≥50 years of age, and to bridge the immune responses induced by VAX-31 in adults 50-64 years of age to adults 18-49 years of age.

Conditions

  • Pneumococcal Disease

Interventions

  • 31 valent pneumococcal conjugate vaccineBiological

    0.5 mL of VAX-31 will be administered into the deltoid muscle

  • PCV20Biological

    0.5 mL of the 20 valent pneumococcal conjugate vaccine will be administered into the deltoid muscle

  • PCV21Biological

    0.5 mL of the 21 valent pneumococcal conjugate vaccine will be administered into the deltoid muscle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Serotype-specific OPA geometric mean titers (GMT) in 50 year olds and aboveTime frame: 1 month after vaccination
  2. Percentage of subjects reporting solicited local adverse events (AE) (redness, swelling, and pain at injection site)Time frame: up to 7 days after vaccination
  3. Percentage of subjects reporting solicited systemic AE (fever, headache, fatigue, muscle pain, and joint pain)Time frame: up to 7 days after vaccination
  4. Percentage of subjects reporting unsolicited AETime frame: up to 31 days after vaccination
  5. Percentage of subjects reporting serious adverse events (SAE), new onset of chronic illness (NOCI), and medically attended adverse events (MAAE)Time frame: up to 6 Months after vaccination
  6. Serotype-specific OPA geometric mean titers (GMT) in 18 to 49 year olds and 50 to 64 year oldsTime frame: 1 month after vaccination

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • Accel Research Site - Achieve - Birmingham - ERN

    Birmingham, Alabama

  • Center for Indigenous Health - Chinle - Johns Hopkins Project

    Chinle, Arizona

  • Center for Indigineous Health - Whiteriver - John Hopkins Project

    Whiteriver, Arizona

  • Clinical Innovations Trials - Riverside - CenExel

    Riverside, California

  • Research Centers of America - Hollywood - CenExel

    Hollywood, Florida

  • Health Awareness - Jupiter - ERN

    Jupiter, Florida

  • Suncoast Research Group LLC

    Miami, Florida

  • Precision Clinical Research - Sunrise

    Sunrise, Florida

  • Clinical Research Atlanta - Headlands

    Stockbridge, Georgia

  • Velocity Clinical Research - Valparaiso (Buynak Clinical Research)

    Valparaiso, Indiana

  • Johnson County Clin-Trials - JCCT

    Lenexa, Kansas

  • Alliance for Multispecialty Research, LLC - West Wichita

    Wichita, Kansas

  • DelRicht Clinical Research, LLC - New Orleans

    New Orleans, Louisiana

  • Headlands Research - Detroit - Headlands

    Southfield, Michigan

  • DelRicht Research, LLC - Gulfport

    Gulfport, Mississippi

  • Sky Integrative Medical Center - SKYCRNG

    Ridgeland, Mississippi

  • Alliance for Multispecialty Research, LLC - Kansas City

    Kansas City, Missouri

  • Velocity Clinical Research

    Omaha, Nebraska

  • Advanced Memory Research Institute - CenExe

    Toms River, New Jersey

  • Center for Indigineous Health - Gallup - John Hopkins Project

    Gallup, New Mexico

  • Center for Indigineous Health - Shiprock - John Hopkins Project

    Shiprock, New Mexico

  • Rochester Clinical Research - ATLAS - Rochester

    Rochester, New York

  • CTI Clinical Research Center

    Cincinnati, Ohio

  • Lynn Institute of Norman

    Norman, Oklahoma

  • DM Clinical Research - Philadelphia

    Philadelphia, Pennsylvania

  • Coastal Carolina Research Center - Alcanza - HyperCore

    North Charleston, South Carolina

  • Flourish Research - San Antonio

    San Antonio, Texas

  • DM Clinical Research - Sugarland

    Sugar Land, Texas

  • JBR Clinical Research - CenExel JBR

    Salt Lake City, Utah

  • Charlottesville Medical Research Center - Alcanza - HyperCore

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.